Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients - PubMed (original) (raw)
Clinical Trial
. 1997 May 1;89(9):3354-60.
G Q Chen, J H Ni, X S Li, S M Xiong, Q Y Qiu, J Zhu, W Tang, G L Sun, K Q Yang, Y Chen, L Zhou, Z W Fang, Y T Wang, J Ma, P Zhang, T D Zhang, S J Chen, Z Chen, Z Y Wang
Affiliations
- PMID: 9129042
Free article
Clinical Trial
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
Z X Shen et al. Blood. 1997.
Free article
Abstract
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at the dose of 10 mg/d. Clinical CR was achieved in nine of 10 (90%) patients treated with As2O3 alone and in the remaining five patients treated by the combination of As2O3 and low-dose chemotherapeutic drugs or ATRA. During the treatment with As2O3, there was no bone marrow depression and only limited side effects were encountered. Pharmacokinetic studies, which were performed in eight patients, showed that after a peak level of 5.54 micromol/L to 7.30 micromol/L, plasma arsenic was rapidly eliminated, and the continuous administration of As2O3 did not alter its pharmacokinetic behaviors. In addition, increased amounts of arsenic appeared in the urine, with a daily excretion accounting for approximately 1% to 8% of the total daily dose administered. Arsenic contents in hair and nail were increased, and the peak content of arsenic could reach 2.5 to 2.7 microg/g tissue at CR. On the other hand, a decline of the arsenic content in hair and nail was observed after withdrawal of the drug. We conclude that As2O3 treatment is an effective and relatively safe drug in APL patients refractory to ATRA and conventional chemotherapy.
Similar articles
- [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Tanaka Y, Komatsu H, Ishii K, Nakamura F, Hayashi T, Sawada H, Ono Y, Imanaka T. Tanaka Y, et al. Rinsho Ketsueki. 2000 Apr;41(4):354-7. Rinsho Ketsueki. 2000. PMID: 10846468 Japanese. - Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Niu C, et al. Blood. 1999 Nov 15;94(10):3315-24. Blood. 1999. PMID: 10552940 Clinical Trial. - Long-term survey of outcome in acute promyelocytic leukemia.
Hu J, Shen Z, Sun H, Wu W, Li X, Sun G, Wang Z. Hu J, et al. Chin Med J (Engl). 2000 Feb;113(2):107-10. doi: 10.3901/jme.2000.08.107. Chin Med J (Engl). 2000. PMID: 11775530 - Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY, Yang CH, Chen YC. Huan SY, et al. Leuk Lymphoma. 2000 Jul;38(3-4):283-93. doi: 10.3109/10428190009087019. Leuk Lymphoma. 2000. PMID: 10830735 Review. - Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Chen Z, et al. Semin Hematol. 2001 Jan;38(1):26-36. doi: 10.1053/shem.2001.20863. Semin Hematol. 2001. PMID: 11172537 Review.
Cited by
- TRIM44 enhances autophagy via SQSTM1 oligomerization in response to oxidative stress.
Wang Y, Lyu L, Vu T, McCarty N. Wang Y, et al. Sci Rep. 2024 Aug 16;14(1):18974. doi: 10.1038/s41598-024-67832-x. Sci Rep. 2024. PMID: 39152142 Free PMC article. - Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy in patients with newly diagnosed glioblastoma.
Ryu S, Ye X, Olson JJ, Mikkelsen T, Bangiyev L, Lesser GJ, Batchelor T, Nabors B, Desideri S, Walbert T, Grossman SA. Ryu S, et al. Neurooncol Adv. 2024 Jun 13;6(1):vdae089. doi: 10.1093/noajnl/vdae089. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38978961 Free PMC article. - Bringing global hematology research to the forefront.
Gómez-De León A, Noyola-Pérez A, Gil-Flores L, Malhotra H, Musteata V, El-Beshlawy A, Tadjoedin H, Pavlovsky C, Cortes J. Gómez-De León A, et al. Blood Adv. 2024 Jul 23;8(14):3607-3611. doi: 10.1182/bloodadvances.2023011873. Blood Adv. 2024. PMID: 38739717 Free PMC article. - History of Developing Acute Promyelocytic Leukemia Treatment and Role of Promyelocytic Leukemia Bodies.
Bercier P, de Thé H. Bercier P, et al. Cancers (Basel). 2024 Mar 29;16(7):1351. doi: 10.3390/cancers16071351. Cancers (Basel). 2024. PMID: 38611029 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources